SYRE · Healthcare
Spyre Therapeutics Inc
16/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
21
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$8.9B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About SPYRE THERAPEUTICS INC
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is…
Who's behind the signal
Every informed buyer we can see on SYRE, across all three feeds.
Hedge funds · 4
Millennium Management (Englander)
Increased +92%
Citadel Advisors
Increased +69%
AQR Capital Management
Increased +17%
Tudor Investment (Paul Tudor Jones)
Decreased −17%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
SPYRE THERAPEUTICS INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
0
New positions
3
Increasing
1
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+92%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+69%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+17%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
−17%
0.0% of Tudor Investment's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to SPYRE THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell SPYRE THERAPEUTICS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime